Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_003919.3(SGCE):c.724C>T(p.Pro242Ser) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
SGCE (HGNC:10808): (sarcoglycan epsilon) This gene encodes the epsilon member of the sarcoglycan family. Sarcoglycans are transmembrane proteins that are components of the dystrophin-glycoprotein complex, which link the actin cytoskeleton to the extracellular matrix. Unlike other family members which are predominantly expressed in striated muscle, the epsilon sarcoglycan is more broadly expressed. Mutations in this gene are associated with myoclonus-dystonia syndrome. This gene is imprinted, with preferential expression from the paternal allele. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. A pseudogene associated with this gene is located on chromosome 2. [provided by RefSeq, Oct 2016]
CASD1 (HGNC:16014): (CAS1 domain containing 1) Enables N-acetylneuraminate 7-O(or 9-O)-acetyltransferase activity. Involved in carbohydrate metabolic process. Is integral component of Golgi membrane. [provided by Alliance of Genome Resources, Apr 2022]
This sequence change replaces proline with serine at codon 242 of the SGCE protein (p.Pro242Ser). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and serine. In summary, this variant is a novel missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with an SGCE-related disease. -
.;.;.;.;.;Loss of catalytic residue at P278 (P = 0.07);.;.;.;.;.;.;.;.;.;Loss of catalytic residue at P278 (P = 0.07);.;.;.;.;Loss of catalytic residue at P278 (P = 0.07);.;.;.;.;.;.;Loss of catalytic residue at P278 (P = 0.07);Loss of catalytic residue at P278 (P = 0.07);.;.;.;Loss of catalytic residue at P278 (P = 0.07);Loss of catalytic residue at P278 (P = 0.07);.;.;